Abstract P152: Urinary isoflavonoids and Risk of Type 2 Diabetes: A Prospective Investigation in U.S. Women
Objective: To examine the association between urinary excretions of isoflavonoids and risk of type 2 diabetes (T2D).
Methods: Urinary excretions of daidzein and genistein, as well as their metabolites desmethylangolensin (DMA), dihydrogenistein (DHGE), dihydrodaidzein (DHDE) were assayed by liquid chromatography mass spectrometry among 1,111 T2D nested case-control pairs identified during 1995 - 2008 in the Nurses’ Health Study (NHS; aged 54 - 80y, 99% postmenopausal) and NHSII (aged 33 - 52y, 22% postmenopausal) who were free of diabetes, cardiovascular disease, and cancer at urine sample collection in 1995-2001. Incident self-reported T2D cases were confirmed using a validated supplementary questionnaire.
Results: Total urinary isoflavones and all individual metabolites except DMA were associated with a lower risk of T2D in the NHS but not in the younger women of the NHSII. Compared to the lowest tertile of total urinary isoflavones, the odds ratios (ORs) of T2D in the middle and high tertile of NHS were 0.72 (95% CI: 0.49, 1.04) and 0.57 (95% CI: 0.38, 0.85) (P for trend = 0.01), respectively. In contrast, the corresponding ORs (95% CIs) were 0.99 (0.65, 1.50) and 1.21 (0.79, 1.85) in NHSII. Significant heterogeneity was found between the two cohorts for the associations of daidzein, DMA, and total isoflavones (P < 0.05). A significant effect modification by postmenopausal hormone use was found in the NHS, with a stronger inverse association observed among these postmenopausal women who did not use hormone therapy.
Conclusions: Inverse associations between urinary isoflavones and risk of T2D were found in older women, especially those who did not use postmenopausal hormone, whereas in younger women no association was observed.
Author Disclosures: M. Ding: None. A. Franke: None. B. Rosner: None. R. van Dam: None. S. Tworoger: None. F. Hu: None. Q. Sun: None.
- © 2015 by American Heart Association, Inc.